We, LTT Bio-Pharma, have been applying cutting-edge science and technology to medicine for more than 30 years, have been conducting research and development to protect the health and lives of people all over the world.
Research and Development
We will introduce our original drug discovery technologies, pipeline under development, and launched drugs.
DR
Drug Repositioning
We were the first in Japan to point out the importance of DR and have been promoting drug discovery as a leading
DR company. We are also engaged in collaborative research using our own original library of approved drugs.
DDS
Drug Delivery System
Like DR, DDS contributes to early commercialization and reduced development risk. We have launched DDS new drug and are still developing new drugs using the world’s first DDS technology.
Collaborative R&D
and Consultation
Through joint development, we connect academia and pharmaceutical companies to efficiently develop pharmaceuticals.
Founding Family
創業者と創業家 / 水島徹 & 水島広子
Corporate Information
Careers
IR Information
- All
- Business Development
- Drug Discovery
- General Meeting of Shareholders
- Financial Information
- Other
-
2023.12.25
Announcement of Preliminary Results of Phase II Clinical Trial of PC-SOD
-
2023.12.21
Semi-annual report for the 22nd period has been submitted
-
2023.12.12
Announcement of Phase III Clinical Trial Results for LT-5001
-
2023.12.05
Announcement of Renewal of Business Collaboration Agreement with Sino Biopharmaceutical Co., Ltd.
-
2023.12.05
Report on Participation in BIO Europe 2023 Munich
-
2023.10.17
Report on Exhibit at Japan Healthcare Venture Summit (BioJapan2023)
-
2023.06.16
Report on Participation in BIO International Convention 2023 Boston
-
2023.05.25
Notice of Business Consignment Agreement with a Japanese Company Seeking to Develop Business in China
-
2023.12.05
Announcement of Renewal of Business Collaboration Agreement with Sino Biopharmaceutical Co., Ltd.
-
2023.11.14
Meeting between Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Co., Ltd., and Tohru Mizushima, CEO
-
2023.09.26
Notice of Visit by Mr. Sun Yuhkang, President of Beijing Tide Pharmaceutical Co., LTD. and others to our company
-
2023.07.14
Report on the Courtesy Visit of the Delegation from Beijing Municipal Development Zone to Shonan iPark and our Company